Neogenomics Inc (NEO): Next-Year EPS Estimate 102.53%
As of 2026-06-04, Neogenomics Inc (NEO) has a next-year EPS growth estimate of 102.53%.
On 2026-06-02, analyst consensus for NEO's next-year EPS growth shifted from 102.17% to 102.53% — a positive change of 0.36 percentage points. The revised estimate has been sustained across 3 subsequent trading sessions. Current-year growth is projected at 50.00%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- EPS growth next year
- 102.53%
- EPS growth this year
- 50.00%
- EPS next quarter (est)
- $0.03
- Last price
- $11.31
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 102.53% | 50.00% | $0.03 | $11.31 |
| 2026-06-03 | 102.53% | 50.00% | $0.03 | $10.14 |
| 2026-06-02 | 102.53% | 50.00% | $0.03 | $10.12 |
| 2026-06-01 | 102.17% | 50.27% | $0.03 | $10.44 |
| 2026-05-31 | 102.17% | 50.27% | $0.03 | $10.52 |
| 2026-05-28 | 102.17% | 50.27% | $0.03 | $10.19 |
| 2026-05-27 | 102.17% | 50.27% | $0.03 | $9.57 |
| 2026-05-26 | 102.53% | 50.00% | $0.03 | $9.27 |
| 2026-05-25 | 102.53% | 50.00% | $0.03 | $9.23 |
| 2026-05-24 | 102.53% | 50.00% | $0.03 | $9.23 |
| 2026-05-21 | 102.53% | 50.00% | $0.03 | $9.11 |
| 2026-05-20 | 102.53% | 50.00% | $0.03 | $8.90 |
| 2026-05-19 | 102.53% | 50.00% | $0.03 | $8.39 |
| 2026-05-18 | 102.53% | 50.00% | $0.03 | $8.37 |
| 2026-05-17 | 102.53% | 50.00% | $0.03 | $8.24 |
| 2026-05-14 | 102.53% | 50.00% | $0.03 | $8.36 |
| 2026-05-13 | 102.53% | 50.00% | $0.03 | $8.27 |
| 2026-05-12 | 102.53% | 50.00% | $0.03 | $8.75 |
| 2026-05-11 | 102.53% | 50.00% | $0.03 | $8.66 |
| 2026-05-10 | 102.53% | 50.00% | $0.03 | $8.96 |
| 2026-05-07 | 102.53% | 50.00% | $0.03 | $9.07 |
| 2026-05-06 | 102.53% | 50.00% | $0.03 | $8.89 |
| 2026-05-05 | 97.70% | 50.69% | $0.03 | $8.86 |
| 2026-05-04 | 97.70% | 50.69% | $0.03 | $9.00 |
| 2026-05-03 | 97.70% | 50.69% | $0.03 | $9.44 |
| 2026-04-30 | 97.70% | 50.69% | $0.03 | $9.26 |
| 2026-04-29 | 97.65% | 47.92% | $0.03 | $8.96 |
| 2026-04-28 | 86.24% | 41.97% | $0.01 | $9.02 |
| 2026-04-27 | 86.24% | 41.97% | $0.01 | $8.61 |
| 2026-04-26 | 86.24% | 41.97% | $0.01 | $8.29 |
Recent News
- NeoGenomics Shares Jump on Earnings and Analyst UpgradesInvestorsHub
- NeoGenomics Shares Jump on Earnings and Analyst UpgradesInvestorsHub
- NeoGenomics Inc (NEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...GuruFocus.com
- NeoGenomics Inc (NEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...GuruFocus.com
- NeoGenomics: Q1 Earnings SnapshotAssociated Press
- NeoGenomics: Q1 Earnings SnapshotAssociated Press
- NeoGenomics Reports First Quarter 2026 ResultsBusiness Wire
- NeoGenomics Reports First Quarter 2026 ResultsBusiness Wire
- NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026Business Wire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Neogenomics Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Neogenomics Inc (NEO) has a next-year EPS growth estimate of 102.53%, based on analyst consensus.
When was the latest EPS estimate revision for NEO?▾
The most recent revision occurred on 2026-06-02, when analysts adjusted the next-year EPS growth estimate from 102.17% to 102.53%.
What sector and industry does Neogenomics Inc belong to?▾
Neogenomics Inc operates in the Healthcare sector, specifically the Diagnostics & Research industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. NEO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Neogenomics Inc (NEO) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports